A carregar...
First‐in‐man–proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia
AIMS: Insufficient erythropoietin (EPO) synthesis is a relevant cause of renal anaemia in patients with chronic kidney disease. Molidustat, a selective hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitor, increases endogenous EPO levels dose dependently in preclinical models. We examined...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6005617/ https://ncbi.nlm.nih.gov/pubmed/29575006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13584 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|